Febrile neutropenia

Visão geral 
Teoria 
Diagnóstico 
Tratamento 
ACOMPANHAMENTO 
Recursos 

Conectar-se ou assinar para acessar todo o BMJ Best Practice

Última revisão: 24 Sep 2025

Última atualização: 03 Oct 2025

Febrile neutropenia is an oncologic emergency.

Prompt empiric antibiotic therapy is critical to reduce mortality.

Selecting the optimal agent(s) for empiric therapy should take into account local and regional antibiotic resistance patterns, individual patient history, and presenting signs and symptoms in association with fever.

Due to a decreased ability to mount an inflammatory response, many patients with febrile neutropenia related to a deep-seated focus of infection fail to demonstrate typical localizing signs or symptoms.

Prophylactic antibiotics at the onset of neutropenia can decrease fever and bloodstream infection events in high-risk patients. Use of prophylaxis requires careful risk-benefit assessment and close monitoring for the emergence of antibiotic resistance and antibiotic-associated adverse effects or toxicity.

Definição

Febrile neutropenia is the presence of fever in a patient with neutropenia. It is the most common life-threatening complication of cancer therapy and is considered an oncologic emergency.[1][2]

Febrile neutropenia is defined as a single oral temperature measurement of ≥101ºF (≥38.3ºC) or a temperature of ≥100.4ºF (≥38.0ºC) sustained over 1 hour, with an absolute neutrophil count (ANC) of ≤500 cells/microliter, or an ANC of ≤1000 cells/microliter that is expected to decrease to ≤500 cells/microliter over the next 48 hours.[3][4]

Patients at high risk for medical complications include those: with anticipated duration of severe neutropenia (ANC ≤100 cells/microliter) ≥7 days; undergoing allogeneic hematopoietic stem cell transplant; or, with a significant comorbidity.[4]

Various scoring systems (e.g., Talcott score, Multinational Association of Supportive Care in Cancer [MASCC] score, and Clinical Index of Stable Febrile Neutropenia [CISNE] score) have been proposed to classify risk for serious complications based on factors such as age, comorbidities, vital signs and laboratory results at presentation, and the presence of mucositis.[5][6][7]

História e exame físico

Principais fatores diagnósticos

recent chemotherapy
fever

Detalhes completos

Outros fatores diagnósticos

age >65 years
immunosuppressive therapy
prior chemotherapy-induced neutropenia
low performance status (Eastern Cooperative Oncology Group performance status [ECOG PS] >1)
hematologic malignancies
advanced disease stage
prior antibiotic regimens
low albumin (<3.5 g/dL)
elevated bilirubin and liver enzymes (aspartate aminotransferase and alkaline phosphatase)
preexisting organ dysfunction and comorbid conditions
low first-cycle nadir absolute neutrophil count (<500 cells/microliter)
signs of pneumonia (cough, abnormal breath sounds, shortness of breath)
abdominal pain
nausea or vomiting
diarrhea
skin erythema, warmth, tenderness
mucositis or oral ulcers
infection, inflammation, or ulceration of genital and anal area
infected indwelling catheters
pyuria
chemoradiation therapy
recent historical features and exposures
sinus tenderness

Detalhes completos

Fatores de risco

age >65 years
hematologic malignancies
low albumin (<3.5 g/dL)
elevated bilirubin
elevated liver enzymes
pre-existing organ dysfunction and comorbid conditions
recent chemotherapy
low first-cycle nadir absolute neutrophil count (<500 cells/microliter)
chemoradiation therapy
prior chemotherapy-induced neutropenia
persistent neutropenia (≥7 days)
bone marrow involvement
recent surgery
female sex
low performance status (Eastern Cooperative Oncology Group performance status [ECOG PS] >1)
advanced disease stage
immunosuppressive therapy

Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

CBC and differential
renal function tests (BUN and creatinine)
liver function tests (LFTs)
blood cultures
chest x-ray

Detalhes completos

Investigações a serem consideradas

gastrointestinal pathogen molecular assay
urinalysis and urine culture
lumbar puncture
fungal test
viral molecular assay
echocardiogram
CT scans of the chest, abdomen, and pelvis

Detalhes completos

Algoritmo de tratamento

AGUDA

high risk of complication or death: initial presentation

low risk of complication or death: initial presentation

CONTÍNUA

persistent fever beyond 3-5 days of treatment

Colaboradores

Autores

Lynne Strasfeld, MD

Professor of Medicine

Department of Medicine, Division of Infectious Diseases

Oregon Health and Science University

Portland

Declarações

LS is an author of a reference cited in this topic.

Agradecimentos

Dr Lynne Strasfeld would like to gratefully acknowledge Dr Kenneth V. I. Rolston, Dr Lior Nesher, Dr Caron Jacobson, and Dr Joseph Antin, previous contributors to this topic.

Declarações

KVIR has research grants from Merck, Shionogi, and JMI Laboratories for the performance of in vitro studies of novel antimicrobial agents. LN has given two educational lectures sponsored by MSD. CJ and JA declare that they have no competing interests.

Revisores

Alison Freifeld, MD

Professor of Medicine, Infectious Diseases Division

University of Nebraska College of Medicine

Omaha

Declarações

AF has received payment by Merck for work as an adjudication committee member for clinical trials of letermovir. AF has received an investigator-initiated study grant from Merck.

John Wingard, MD

Price Eminent Scholar and Professor of Medicine

Director

Bone Marrow Transplant Program

Division of Hematology/Oncology

University of Florida College of Medicine

Gainesville

Declarações

JW has been reimbursed by Pfizer, Merck, Astellas, and Enzon for speaking fees, fees for educational programs, and consulting.

Matthew Falagas, MD, MSc, DSc

Director

Alfa Institute of Biomedical Sciences

Marousi

Athens

Greece

Declarações

MF declares that he has no competing interests.

Ruth Pettengell, MBChB FRACP PhD

Senior Lecturer in Haematology

Honorary Consultant in Medical Oncology

St George's University of London

London

Declarações

RP has received speaker fees and been reimbursed by Roche, Amgen, Chigai, and Bayer for attending several conferences. RP is a co-author of the EORTC guidelines referenced in this topic.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 Feb 15;52(4):e56-93.Texto completo Resumo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections [internet publication].Texto completo

Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016 Sep;27(5 suppl):v111-8.Texto completo Resumo

Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Resumo

Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018 Feb 20;36(14):1443-53.Texto completo Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.

Diagnósticos diferenciais
- Drug fever
- Tumor fever
- Thromboembolism
Mais Diagnósticos diferenciais
Diretrizes
- Prevention and treatment of cancer-related infections
- 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies
Mais Diretrizes
Conectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal

Febrile neutropenia

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

Outros fatores diagnósticos

Fatores de risco

Investigações diagnósticas

Primeiras investigações a serem solicitadas

Investigações a serem consideradas

Algoritmo de tratamento

high risk of complication or death: initial presentation

low risk of complication or death: initial presentation

persistent fever beyond 3-5 days of treatment

Colaboradores

Autores

Lynne Strasfeld, MD

Declarações

Agradecimentos

Declarações

Revisores

Alison Freifeld, MD

Declarações

John Wingard, MD

Declarações

Matthew Falagas, MD, MSc, DSc

Declarações

Ruth Pettengell, MBChB FRACP PhD

Declarações

Créditos aos pareceristas

Declarações

Referências

Principais artigos

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.

Diagnósticos diferenciais

Diretrizes

Conectar-se ou assinar para acessar todo o BMJ Best Practice

Conectar-se ou assinar para acessar todo o BMJ Best Practice

Conectar-se para acessar todo o BMJ Best Practice